Adverse Reactions Communication Drug Development 
Pharmaceutical Technology
JUNE 15, 2023
Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. While this process is essential, it’s also slow, expensive and unpredictable.
FDA Law Blog: Biosimilars
MARCH 7, 2024
As another example, both documents note the possibility that if FDA has safety information relevant to an ongoing study, it may request that the sponsor confirm that the DMC is aware of that safety data and is taking it into consideration, or “request that the sponsor arrange for FDA to communicate with, or even meet with, the DMC.”
Expert insights. Personalized for you.
52 
Let's personalize your content